Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Consensus Rating of “Buy” from Brokerages

Krystal Biotech, Inc. (NASDAQ:KRYS) has been assigned a consensus rating of “Buy” from the eleven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $277.8889.

KRYS has been the topic of a number of research reports. Weiss Ratings reissued a “hold (c+)” rating on shares of Krystal Biotech in a research note on Monday, December 29th. Guggenheim set a $224.00 price target on Krystal Biotech and gave the company a “buy” rating in a report on Friday, October 17th. TD Cowen reissued a “buy” rating on shares of Krystal Biotech in a research report on Friday, January 9th. HC Wainwright restated a “buy” rating and set a $310.00 price objective (up previously from $240.00) on shares of Krystal Biotech in a research note on Friday, January 9th. Finally, Zacks Research upgraded Krystal Biotech from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 7th.

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS opened at $269.13 on Thursday. The business has a 50-day moving average of $254.80 and a two-hundred day moving average of $199.79. The firm has a market capitalization of $7.80 billion, a PE ratio of 40.35 and a beta of 0.49. Krystal Biotech has a 12 month low of $122.80 and a 12 month high of $295.98.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $1.54. The business had revenue of $97.80 million during the quarter, compared to analysts’ expectations of $93.72 million. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%. As a group, research analysts anticipate that Krystal Biotech will post 6.14 earnings per share for the current year.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $220.16, for a total value of $5,504,000.00. Following the completion of the sale, the insider owned 1,413,711 shares of the company’s stock, valued at $311,242,613.76. This trade represents a 1.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 13.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Soleus Capital Management L.P. grew its stake in Krystal Biotech by 108.9% during the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after purchasing an additional 481,200 shares in the last quarter. Braidwell LP boosted its stake in Krystal Biotech by 81.6% during the 2nd quarter. Braidwell LP now owns 727,811 shares of the company’s stock valued at $100,045,000 after purchasing an additional 327,067 shares during the period. Norges Bank bought a new position in Krystal Biotech in the 2nd quarter worth about $38,861,000. First Trust Advisors LP increased its stake in shares of Krystal Biotech by 571.3% in the second quarter. First Trust Advisors LP now owns 222,370 shares of the company’s stock valued at $30,567,000 after purchasing an additional 189,245 shares during the period. Finally, UBS Group AG increased its stake in shares of Krystal Biotech by 970.8% in the fourth quarter. UBS Group AG now owns 159,595 shares of the company’s stock valued at $39,347,000 after purchasing an additional 177,922 shares during the period. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.